Experimental models for nephropathy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 4, 2008, Pages 189-195

  Balakumar, Pitchai ^a   Chakkarwar, Vishal Arvind ^a   Kumar, Vijay ^b   Jain, Akash ^a   Reddy, Jayarami ^a   Singh, Manjeet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b LOVELY PROFESSIONAL UNIVERSITY   (India)

Author keywords

Animal models; Nephropathy; Signalling mechanisms

Indexed keywords

CADMIUM; CARBON TETRACHLORIDE; CISPLATIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETHYLENE GLYCOL; FIBROBLAST GROWTH FACTOR 2; GENTAMICIN; GERMANIUM DIOXIDE; HYDROCORTISONE ACETATE; INTERLEUKIN 1; INTERLEUKIN 6; MALEIC ACID; MERCURIC CHLORIDE; PLATELET DERIVED GROWTH FACTOR; PUROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; UREA; VOMITOXIN;

CAUSAL ATTRIBUTION; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DIABETIC NEUROPATHY; DISEASE COURSE; DOWN REGULATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TARGETING; ELECTROLYTE DISTURBANCE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GLOMERULOSCLEROSIS; HYPERLIPIDEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; NONHUMAN; PROTEINURIA; REVIEW; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HUMAN; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES;

EID: 66149137665     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320308098343     Document Type: Review

References (65)

1. Ogi M., Kojima S., Kuramochi M. Effect of postural change on urine volume and urinary sodium excretion in diabetic nephropathy. Am J Kidney Dis 1998;31:41-8.
2. Blickle JF, Doucet J., Lrummel T., Hannedouche T. Diabetic nephropathy in the elderly. Diabetes Metab 2007;33:S40-S55.
3. Casey GR, Joyce M., Nagle RG, Chen G., Hayes D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2004;123:176-81.
4. Kurus M., Esrefoglu M., Bay A., Ozturk F. Protective effect of oral L-arginine supplementation on ciclosporin induced nephropathy in rats. Int Urol Nephrol 2005;37:587-94.
5. Koike N., Takamura T., Kaneko S. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-stimulation, and effects of a phosphodiesterase inhibitor. Life Sci 2007;80:1721-8.
6. Khamaisia M., Keynana S., Bursztyna M. et al. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol 2007;102:72-80.
7. Tain L., Freshour G., Dikalova A., Griendling K., Baylis C. Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 2007;292:F1404-F1410.
8. Erdely A., Freshour G., Smith C. et al. Protection against puromycin aminonucleoside-induced chronic renal disease in the wistar-furth rat. Am J Physiol Renal Physiol 2007;287:F81-F91.
9. Lee EY, Shim MS, Kim MJ, Hong SY, Shin Y., Chung CH Angiotensin II receptor blocker attenuates overexpression vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;1:65-70.
10. Hocher B., Schwarz A., Reinbacher D. et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87:161-9.
11. Tahara A., Tsukada J., Tomura Y., Suzuki T., Yatsu T., Shibasaki M. Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol 2008;35:586-93.
12. Sidhart PN, Wagner FD, Bohnemeier H., Jungnik A., Halabi A., Dingemanse S. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006;80:246-56.
13. Matsumoto Y., Ueda S., Yamagishi S. et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007;18:1365-7.
14. Valles PG, Manucha W., Carrizo L., Vega PJ, Seltzer A., Ruete C. Renal caveolin-1 expression in children with unilateral ureteropelvic junction obstruction. Pediatr Nephrol 2007;22:273-83.
15. Won CJ, Kim CS, Kim SB, Park SK, Park JS, Lee SK C-reactive protein induces NF-κ activation through intracellular calcium and ROS in human mesangial cells. Nephron Exp Nephrol 2005;101:e165-e172.
16. Lee Mp-S, Orlov D., Sweeney G. Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis. Int J Obes 2005;29:1395-401.
17. Ellington AA, Malik AR, Klee GG et al. Association of plasma resistin with glomerular filtration rate albuminuria in hypertensive adults. Hypertension 2007;50:708-14.
18. Gojo A., Utsunomiya K., Taniguchi K. et al. The Rho-kinase inhibitior, fasudil, attenuates diabetic nephropathy in strepazotocin-induced diabetic rats. Eur J Pharm 2007;568:242-7.
19. Zhao HJ, Wang S., Cheng H. et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17:2664-9.
20. Balakumar P., Jindal S., Singh M. Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction in rats. J Pharmacol Toxicol 2007;2:437-46.
21. Jindal S., Singh M., Balakumar P. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol 2008;128:383-91.
22. Balakumar P., Kaur T., Singh M. Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology 2008;245:49-64.
23. Balakumar P., Koladiya RU, Ramasamy S., Rathinavel A., Singh M. Pharmacological interventions to prevent vascular endothelial dysfunction: Future directions. J Health Sci 2008;54:1-16.
24. Shah DI, Singh M. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction. Vascul Pharmacol 2006;44:177-82.
25. Singh J., Budhiraja S., Lal H., Arora BR Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy. Iran J Pharmacol Ther 2006;5:135-9.
26. Al-Qattan K., Thomson M., Ali M. Garlic (Allium sativum) and ginger (Zingiber officinale) attenuate structural nephropathy progression in streptozotocin-induced diabetic rats. Eur J Clin Nutr Metab 2008;3:e62-e71.
27. Haidara MA, Mikhailidisc DP, Rateba MA et al. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced type 1 diabetes. J Diabetes Complications 2008; (In press).
28. Szabo C. Roles of poly (ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005;52:60-7.
29. Yokozawa T., Nakagawa T., Wakaki W., Koizumi F. Animal model of diabetic nephropathy. Exp Toxicol Pathol 2001;53:359-63.
30. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrol Dial Transplant 2004;19:2987-96.
31. Sato N., Komatsu K., Kurumatani H. Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol 2003;23:334-42.
32. Bitara MS, Wahida S., Mustafa S. et al. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 2005;511:53-64.
33. Sugimoto H., Grahovac G., Zeisberg M., Kalluril R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007;56:1825-33.
34. Forsell T., Ruutu M., Isoniemi H., Ahonen J., Alfthan O. Cyclosporine in severe interstitial cystitis. J Urol 1996;155:1591-3.
35. Lloveras J. Use of cyclosporine in renal transplantation. Trans Proc 2004;36:107S-113S.
36. Li C., Yang CW, Park JH, Lim SW, Sun BK, Jung Y. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004;1286:F46-F57.
37. Bing P., Maode L., Li F., Sheng H. Expression of renal transforming growth factor-β and its receptors in a rat model of chronic cyclosporine-induced nephropathy. Trans Proc 2006;38:2176-9.
38. LaSpina M., Tripathi S., Gatto LA, Bruch D., Maier KG, Kittur DS An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice. J Surg Res 2008;148:121-5.
39. Singal P., Iliskovic NS, Hill M., Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27:1055-63.
40. Hahn H., Park YS, Ha S., Cheong H., Choi Y. Age-related differences in adriamycin-induced nephropathy. Pediatr Nephrol 2004;19:761-6.
41. Sakemi T., Ohtsuka N., Tomiyoshi Y., Morito F. Sex difference in progression of adriamycin-induced nephropathy in rats. Am J Nephrol 1996;16:540-7.
42. Mune M., Otani H., Yukawa S. Effects of antioxidants on kidney disease. Mech Ageing Dev 2002;123:1041-6.
43. Malarkodi KP, Varalakshmi P. Lipoic acid as a rescue agent for adriamycin-induced hyperlipidemic nephropathy in rats. Nutr Res 2003;23:539-48.
44. Shimizu K., Shibata M. A study of daunomycin rats - is it possible to use daunomycin rats as an experimental model of chronic renal failure? Nippon Jinzo Gakkai Shi 1989;31:345-51.
45. Ohtake T., Kimura M., Nishimura M., Hishida A. Roles of reactive oxygen species and antioxidant enzymes in murine daunomycin-induced nephropathy. J Lab Clin Med 1997;129:81-8.
46. Ohtake T., Kimura M., Takemura H., Hishida A. Effects of dietary lipids on daunomycin-induced nephropathy in mice: Comparison between cod liver oil and soybean oil. Lipids 2002;37:359-66.
47. Gvozdenko TA, Novgorodtseva TE, Vostrikova OG, Kapitonova VG Simulation of electrolyte nephropathy in rats. Bull Exp Biol Med 2004;138:238-40.
48. Corley RA, Wilson DM, Hard GC et al. Dosimetry considerations in the enhanced sensitivity of male wistar rats to chronic ethylene glycol-induced nephrotoxicity. Toxicol Appl Pharmacol 2008;228:165-78.
49. Hanslik T., Blanchet F., Nochy D. et al. Effect of the platelet activating factor antagonist BN52021 in rabbits: Role in gentamicin nephrotoxicity. Toxicol Appl Pharmacol 1994;128:111-15.
50. Kumar VK, Naidu Mur, Shifow A., Ratnakar KS Probucol protects against gentamicin-induced nephrotoxicity in rats. Indian J Pharmacol 2000;32:108-13.
51. Cuzzocrea S., Mazzon E., Dugo L. et al. A role for super-oxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2002;450:67-76.
52. Pedraza-Chaverri J., Barrera D., Hernandez-Pando R., Medina-Campos ON, Cruz C., Murgui F. Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. Life Sci 2004;74:987-99.
53. Leffler PE, Jin T., Nordberg GF Nephrotoxic impact of multiple short-interval cadmium-metallothionein injections in the rat. Toxicology 1996;112:151-6.
54. Uriu K., Kaizu K., Komine N. et al. Renal hemodynamics in rats with cadmium-induced nephropathy. Toxicol Appl Pharmacol 1998;150:76-85.
55. Takaki A., Jimi S., Segawa M., Iwasaki H. Cadmium-induced nephropathy in rats is mediated by expression of senescenceassociated beta-galactosidase and accumulation of mitochondrial DNA deletion. Ann N Y Acad Sci 2004;101:332-8.
56. Junnila M., Rahko T., Sukura A., Lindberg LA Reduction of carbon tetrachloride-induced hepatotoxic effects by oral administration of betaine in male han-wistar rats: A morphometric histological study. Vet Pathol 2000;37:231-8.
57. Ogeturk M., Kus I., Kavakli A., Oner J., Kukner A., Sarsilmaz M. Reduction of carbon tetrachloride-induced nephropathy by melatonin administration. Cell Biochem Funct 2005;23:85-92.
58. Yanagisawa H., Yamazaki N., Sato G., Wada O. L-Arginine treatment may prevent tubulointerstitial nephropathy caused by germanium dioxide. Kidney Int 2000;57:2275-84.
59. Sampaio-Maia B., Moreira-Rodrigues M., Serrao P., Pestana M. Blunted renal dopaminergic system activity in HgCl2-induced membranous nephropathy. Life Sci 2006;78:1246-55.
60. Osman AM, El-Sayed EM, El-Demerdash E., Al- Hyder A., El- Didi M., Attia A. Prevention of cisplatin-induced nephrotoxicity by methimazole. Pharmacol Res 2000;41:115-21.
61. Saad SY, Arafah MM, Najjar TA Effect of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chem Pharmacol 2007;59:455-60.
62. Floege J., Feehally J. IgA nephropathy: Recent developments. Am Soc Nephrol 2000;11:2395-403.
63. Jia Q., Zhou HR, Bennink M., Pestka JJ Docosahexaenoic acid attenuates mycotoxin-induced immunoglobulin A nephropathy, interleukin-6 transcription, and mitogen-activated protein kinase phosphorylation in mice. J Nutr 2004;134:3343-9.
64. Mujais SK Maleic acid-induced proximal tubulopathy: Na:K pump inhibition. J Am Soc Nephrol 1993;4:142-7.
65. Silverman M. The mechanism of maleic acid nephropathy: Investigations using brush border membrane vesicles. Mol Membr Biol 1981;4:63-9.